<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04494815</url>
  </required_header>
  <id_info>
    <org_study_id>SR419-102</org_study_id>
    <nct_id>NCT04494815</nct_id>
  </id_info>
  <brief_title>A Phase 1b Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SR419</brief_title>
  <official_title>A Phase 1b, Randomised, Double-blind, Placebo- and Active Controlled, Single Dose Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SR419 in Patients With Peripheral Neuropathic Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SIMR (Australia) Biotech Pty Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai SIMR Biotechnology Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SR419&#xD;
      in Patients with Peripheral Neuropathic Pain&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single center, three-period, complete crossover, double-blind, randomised, placebo-&#xD;
      and active-controlled study to compare the preliminary efficacy of a single dose of SR419 to&#xD;
      placebo and active control in patients with peripheral neuropathic pain. The study also aims&#xD;
      to evaluate the safety, tolerability, and PK of single doses of SR419 in patients with&#xD;
      peripheral neuropathic pain.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 18, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>QST of an affected area.</measure>
    <time_frame>Up to Day18(-2~+5) for the safety follow up since Day1</time_frame>
    <description>QST: Quantitative sensory testing</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The incidence, frequency, and severity of TEAEs.</measure>
    <time_frame>Up to Day18(-2~+5) for the safety follow up since Day1</time_frame>
    <description>TEAE: Treatment-Emergent Adverse Events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spontaneous pain score</measure>
    <time_frame>Up to Day18(-2~+5) for the safety follow up since Day1</time_frame>
    <description>Pain score will be assessed via painDETECT questionnaire with a value range of 0~38, which includes three situations: If a subject gets a score of 0~12, it means a neuropathic pain component is unlikely(less than 15% probability); if a score of 13~19, it means the result is ambiguous, however, a neuropathic pain component can be present; if the score is equal to or greater than nineteen, it means a neuropathic pain is likely(more than 90% probability).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QST of an unaffected area.</measure>
    <time_frame>Up to Day18(-2~+5) for the safety follow up since Day1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of SR419 after dosing.</measure>
    <time_frame>Up to Day11(+3)</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Peripheral Neuropathic Pain</condition>
  <arm_group>
    <arm_group_label>Treatment A+Treatment B+Treatment C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment A: Single 20 mg oral suspension dose of SR419 + single active control placebo capsule.&#xD;
Treatment B: Single SR419 placebo oral suspension + single 300 mg oral capsule of active control.&#xD;
Treatment C: Single SR419 placebo oral suspension + single active control placebo capsule.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment A+Treatment C+Treatment B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B+Treatment A+Treatment C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B+Treatment C+Treatment A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment C+Treatment A+Treatment B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment C+Treatment B+Treatment A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SR419</intervention_name>
    <description>Each participant will receive 1 dose of 20 mg SR419 oral suspension.</description>
    <arm_group_label>Treatment A+Treatment B+Treatment C</arm_group_label>
    <arm_group_label>Treatment A+Treatment C+Treatment B</arm_group_label>
    <arm_group_label>Treatment B+Treatment A+Treatment C</arm_group_label>
    <arm_group_label>Treatment B+Treatment C+Treatment A</arm_group_label>
    <arm_group_label>Treatment C+Treatment A+Treatment B</arm_group_label>
    <arm_group_label>Treatment C+Treatment B+Treatment A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>active control</intervention_name>
    <description>Each participant will receive 1 dose of 300 mg active control capsule.</description>
    <arm_group_label>Treatment A+Treatment B+Treatment C</arm_group_label>
    <arm_group_label>Treatment A+Treatment C+Treatment B</arm_group_label>
    <arm_group_label>Treatment B+Treatment A+Treatment C</arm_group_label>
    <arm_group_label>Treatment B+Treatment C+Treatment A</arm_group_label>
    <arm_group_label>Treatment C+Treatment A+Treatment B</arm_group_label>
    <arm_group_label>Treatment C+Treatment B+Treatment A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SR419 placebo</intervention_name>
    <description>Each participant will receive 2 doses of SR419 placebo oral suspension.</description>
    <arm_group_label>Treatment A+Treatment B+Treatment C</arm_group_label>
    <arm_group_label>Treatment A+Treatment C+Treatment B</arm_group_label>
    <arm_group_label>Treatment B+Treatment A+Treatment C</arm_group_label>
    <arm_group_label>Treatment B+Treatment C+Treatment A</arm_group_label>
    <arm_group_label>Treatment C+Treatment A+Treatment B</arm_group_label>
    <arm_group_label>Treatment C+Treatment B+Treatment A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>active control placebo</intervention_name>
    <description>Each participant will receive 2 doses of active control placebo capsule.</description>
    <arm_group_label>Treatment A+Treatment B+Treatment C</arm_group_label>
    <arm_group_label>Treatment A+Treatment C+Treatment B</arm_group_label>
    <arm_group_label>Treatment B+Treatment A+Treatment C</arm_group_label>
    <arm_group_label>Treatment B+Treatment C+Treatment A</arm_group_label>
    <arm_group_label>Treatment C+Treatment A+Treatment B</arm_group_label>
    <arm_group_label>Treatment C+Treatment B+Treatment A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Aged ≥18 years at the time of informed consent.&#xD;
&#xD;
          2. Be diagnosed as suffering from chronic peripheral neuropathic pain, and specifically&#xD;
             PHN or DPN.&#xD;
&#xD;
          3. Average daily pain over the last week prior to Screening to be of at least moderate&#xD;
             severity (a score of ≥4 on the 11-point numeric rating scale [NRS]) and be of face,&#xD;
             limb or torso location.&#xD;
&#xD;
          4. A minimum score of 19 on the pain DETECT questionnaire.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Being pregnant or lactating at Screening or planning to become pregnant (self or&#xD;
             partner) at any time during the study.&#xD;
&#xD;
          2. Prior or ongoing medical conditions, medical history, physical findings, or laboratory&#xD;
             abnormality.&#xD;
&#xD;
          3. Known or suspected intolerance or hypersensitivity to any of the study drugs, close&#xD;
             related compounds, or any of the stated ingredients.&#xD;
&#xD;
          4. Participants on controlled-release opioids (e.g., morphine) unless on a stable dose of&#xD;
             Morphine Equivalent Dose (assessed by the Faculty of Pain Medicine Opioids Calculator)&#xD;
             of up to and including 60 mg/day, at the discretion of the Investigator. Participants&#xD;
             on instant-release opioids (e.g., codeine, oxycodone) must withhold dosing for 12&#xD;
             hours prior to administration of study drug.&#xD;
&#xD;
          5. Positive testing for human immunodeficiency virus (HIV), hepatitis B surface antigen&#xD;
             (HBsAg), or hepatitis C virus (HCV).&#xD;
&#xD;
          6. Creatinine clearance as estimated by estimated glomerular filtration rate (eGFR) &lt;60&#xD;
             mL/min.&#xD;
&#xD;
          7. A history of major psychiatric disorder(s).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kai Wu</last_name>
    <role>Study Director</role>
    <affiliation>SIMR</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tina Zhao</last_name>
    <phone>+86 021 61161537</phone>
    <email>contact@simrbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinical Research Facility Medical School, University of Adelaide</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>July 28, 2020</study_first_submitted>
  <study_first_submitted_qc>July 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 31, 2020</study_first_posted>
  <last_update_submitted>August 5, 2021</last_update_submitted>
  <last_update_submitted_qc>August 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DPN, PHN...etc.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuralgia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

